Johnson & Johnson Q4 Profit Decreases

Johnson & Johnson stock down despite beat on full-year, Q4 2024 earnings
Johnson & Johnson (JNJ) beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to about $143 per share. Several negative impacts were highlighted in the look-back and look-ahead on an earnings call,
Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth
Johnson & Johnson unveiled financial results that beat Wall Street expectations as the company braces for one of its top-selling medicines, Stelara, to go off patent in the coming weeks.Fourth-quarter sales,
Johnson & Johnson Q4 Profit Decreases, But Beats Estimates
Johnson & Johnson (JNJ) announced a profit for fourth quarter that decreased from last year but beat the Street estimates. The
Johnson & Johnson (JNJ) Q4 2024 Earnings Call Transcript
Operator Good morning and welcome to Johnson & Johnson's fourth quarter 2024 earnings conference call. All participants will be in a listen-only mode until the question-and-answer session of the conference.
Johnson & Johnson Dips On Q4 Earnings: Here's What The Market Isn't Seeing
Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ stock is a Buy.
Johnson & Johnson (JNJ) Q4 Earnings and Revenues Top Estimates
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $2.29 per share a year ago. These figures are adjusted for non-recurring items.
Johnson & Johnson: Hold Rating Amid Mixed Performance and Future Uncertainties
Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...
Johnson & Johnson's MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analyst
Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.
The Motley Fool1d
Johnson & Johnson (NYSE: JNJ)
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments ...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Johnson & Johnson (JNJ) And Encourages Shareholders to Connect
NEW YORK, NY / ACCESS Newswire / January 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...
TipRanks on MSN4d
Johnson & Johnson’s New Acquisition Could Result in Tremendous Rewards
Staying ahead of the competition is critical in every sector, particularly in the dynamic healthcare space, where a single ...
Johnson & Johnson Tops Q4 EPS Forecasts
Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.
MarketBeat on MSN6d
Is Johnson & Johnson Stock Set to Reward Long-Term Holders?
Johnson & Johnson (NYSE: JNJ) stock is up 1.8% in the five days after the company announced its $14.6 billion acquisition of ...
Johnson & Johnson's SWOT analysis: stock outlook amid pipeline progress, biosimilar challenges
Johnson & Johnson (NYSE:JNJ), a global healthcare leader, finds itself at a pivotal juncture as it navigates a landscape of ...